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Both extrinsic and intrinsic factors predispose older people to fall. We performed a genome-
wide association analysis to investigate how much of an individual’s fall susceptibility can be
attributed to genetics in 89,076 cases and 362,103 controls from the UK Biobank Study. The
analysis revealed a small, but significant SNP-based heritability (2.7%) and identified three
novel fall-associated loci (Pcombined≤ 5 × 10−8). Polygenic risk scores in two independent
settings showed patterns of polygenic inheritance. Risk of falling had positive genetic
correlations with fractures, identifying for the first time a pathway independent of bone
mineral density. There were also positive genetic correlations with insomnia, neuroticism,
depressive symptoms, and different medications. Negative genetic correlations were identi-
fied with muscle strength, intelligence and subjective well-being. Brain, and in particular
cerebellum tissue, showed the highest gene expression enrichment for fall-associated
variants. Overall, despite the highly heterogenic nature underlying fall risk, a proportion of the
susceptibility can be attributed to genetics.
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Falls are a growing healthcare problem in older adults. Theyare a major contributor to immobility and premature nur-sing home placement1. Furthermore, they are a leading
cause of unintentional injuries, which require medical treatment2,
and increase the demand on healthcare resources. At present,
between 0.85% and 1.50% of the total healthcare expenditures in
Europe, North America, and Australia are fall-related costs3.
As the global population continues to grow and become older,
healthcare costs related to falls will grow accordingly4.
There are numerous extrinsic and intrinsic factors predisposing
older adults to fall, which have been intensively studied in the
past decades5–7. A number of the intrinsic ones, in particular
postural balance, gait speed, muscle function, and cognition,
have a recognized heritable component8–10, suggesting that
investigation into the genetic influence on falls may be warranted.
Pharmacogenetic variability may also contribute to drug-induced
falls as a result on the variability of drug responses and risk of
adverse effects of medications11,12. Twin studies have found that
familial factors, consisting of genetic and shared environmental
influences, explain about 35% of the variability in the likelihood
of experiencing at least one incident fall and 45% of the variability
in the risk for recurrent falls13. Genetic variation is stable across
the human lifespan and identification of genetic factors for falling
may help optimizing effective fall prevention programs, i.e.,
improve fall risk stratification, while also providing biological
insight into their etiology. So far, few studies have been per-
formed to identify genetic factors underlying fall risk, likely due
to lack of a well-powered discovery setting. In a candidate-gene
study without replication (Ncases= 955; Ntotal= 4163), Judson
et al.14 reported that female carriers of the ACTN3 genetic variant
(rs1815739), which is associated with reduced muscle mass and
force, had 33% higher risk of falling compared to non-carriers.
However, to date, no genome-wide association studies (GWASs)
have been performed to identify genetic variants associated with
increased fall risk in a hypothesis-free context.
Here we undertook the first large-scale GWAS on falling risk in
89,076 cases and 362,103 controls from the UK Biobank Study. We
identified three novel fall-associated loci. Our follow-up analyses
showed falling risk to be a heritable (2.7%), polygenic, and highly
heterogeneous trait genetically correlated with fracture risk and
grip strength among other traits. Brain and, in particular, the
cerebellum tissue showed the highest gene expression enrichment
(false discovery rate < 5%) for fall-associated variants. Overall, our
study provides novel insights into the genetic landscape of falling
risk susceptibility.
Results
GWAS study of falling. Our study included data from 451,179
(89,076 cases) White European individuals (40–69 years) from
the UK Biobank. Fall cases were defined as participants who gave
positive answer to the following question “In the last year have
you had any falls?” We tested 7,745,390 million variants (minor
allele frequency (MAF) > 0.01, imputation quality > 0.3) for
association with fall risk. We identified two loci associated with
fall risk mapping to 7p21.3 near PER4 (rs2709062-A, odds ratio
(OR)= 1.03, P= 3.4 × 10−8) (Fig. 1a) and 19q12 near TSHZ3
(rs2111530-G, OR= 1.03, P= 1.2 × 10−8) (Fig. 1b). Moreover, 58
single-nucleotide polymorphisms (SNPs) were associated at P <
5 × 10−6 of which 15 were associated at genome-wide suggestive
level (P < 5.0 × 10−7) (Table 1 and Supplementary Fig. 1). Linkage
disequilibrium score regression (LDSR) showed no sign of
genomic inflation (Intercept= 1.01) compatible with a polygenic
architecture of the trait and no evidence for stratification (Sup-
plementary Fig. 2). Using a genome-wide gene-based approach,
implemented by MAGMA, we identified nine fall-associated
genes (Supplementary Fig. 3); the MAGMA gene-set results were
later served as an input for the tissue expression analysis. The
majority of the SNPs with P < 5 × 10−6 (Supplementary Fig. 4A)
were located in intergenic or intronic regions and >70% of the
variants overlapped chromatin state annotations (Supplementary
Fig. 4B) of potential involvement in gene regulation; however,
only 3.3% possessed strong (regulomeDB score ≤ 2) regulatory
potential (Supplementary Fig. 4C). The 7p21.3 risk locus did not
harbor genes with relevant expression quantitative trait loci
(eQTL) and/or chromatin interactions (Supplementary Fig. 5A).
The TSHZ3 gene at the 19q12 locus was annotated by eQTLs in
the thyroid tissue and was also implicated by chromatin inter-
actions in the mesendodermal tissue and the mesenchymal stem
cells (Supplementary Fig. 5B). However, none of the lead SNPs
showed any evidence for eQTL effects. In addition, several sug-
gestive SNPs were associated with body composition measures
such as body mass index (BMI), fat mass, and fat-free mass
(Supplementary Table 1).
Replication. We took forward for replication the 17 genome-wide
suggestive SNPs (P < 5.0 × 10−7) from the discovery UK Biobank
(UKBB) sample; we sought replication in two smaller prospective
population-based studies with older participants, namely the
Rotterdam Study (1009 cases and 4925 controls) and B-PROOF
(1206 cases and 1364 controls) cohorts. The B-PROOF Study is
a clinical trial on B-vitamin supplements in older adults of
advanced age (mean age 74.1 ± 6.5 years) in which fall risk was
assessed using retrospective questionnaires at baseline and pro-
spective fall calendars15. The Rotterdam Study is a population-
based cohort with fall information from participants (mean age
69.5 ± 9.2 years) collected retrospectively from baseline ques-
tionnaires16. We defined replication as loci harboring variants
associated at a nominal (P < 0.05) significant threshold in the
replication setting or reaching the genome-wide significant
(GWS) (P < 5.0 × 10−8) threshold in the combined meta-analysis.
Overall, the top two SNPs from the discovery phase remained
GWS significant in the combined meta-analysis, while replication
also brought one additional locus (5q21.3) mapping to RP11-
6N13.1 above the GWS threshold (Table 1 and Fig. 1c). The lead
SNP in this locus did not show any evidence for eQTL effects
(Supplementary Fig. 5c).
Polygenic risk scores. Next, we evaluated the ability of polygenic
risk scores (PRSs) constructed from the UK Biobank GWAS
results to discriminate between fallers and non-fallers in two
independent prospective cohorts. We hypothesized falling risk to
follow a polygenic mode inheritance, i.e., is influenced by
numerous genes with small individual effects17 and, hence, non-
GWS SNPs may also contribute to the genetic component of
falling risk. Therefore, PRSs were constructed using PRSice18 for a
series of P-value thresholds ranging from 5 × 10−8 to 1. Variants
(P < 1, MAF > 0.05, and imputation quality > 0.3) were clumped
before analysis (r2 < 0.05, window: 300 kb) to obtain the most
significant SNP in the locus. In line with polygenic inheritance,
the PRS explained a small, but robust, proportion of the trait
variance (max R2= 0.29%) along different P-value thresholds. In
the B-PROOF Study, the PRS derived from GWS variants (P ≤
5 × 10−8) was associated with prospective falls (reported by fall
calendar) and explained the largest fraction of the trait variance
(max R2= 0.29%) (Supplementary Data 1 and Fig. 2a). In con-
trast, the PRSs constructed from variants in the lower significance
thresholds (P ≤ 0.03) were the ones more strongly associated with
retrospectively collected falls (reported by baseline ques-
tionnaires) (Supplementary Data 1 and Fig. 2b, c).
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Fig. 1 Regional association plots of the associated loci. In each plot, the −log10 of p-values are on the left y-axis, the SNP genomic position (hg19) on the
x-axis, and the estimated recombination rate from 1000 genomes (March 2015 EUR) are on the right y-axis and plotted in blue. SNPs are colored red to
reflect linkage disequilibrium (LD) with the most significant SNP in purple (pairwise r2 from 1000 genomes March 2014 EUR). (a) 7p21.3, (b) 19q12, and
(c) 5q21.2 loci.
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Individual and shared heritability of falls. We then used LDSR
to estimate the heritability (individual and shared) between falls
and different diseases and traits19, restricting the analysis to
common variants (MAF > 5%) present in HapMap3. We con-
sidered traits that are closely phenotypically related with fall risk
such as musculoskeletal, neurological, and psychological ones,
and use of a variety of medications. As expected, the SNP-based
heritability of falls was low (h2= 0.027, SE= 0.002). In relation to
other traits (Supplementary Data 2 and Fig. 3), falling had a
positive genetic correlation with fracture (rg= 0.45, SE= 0.05,
p= 5.0 × 10−21) and was negatively genetically correlated (rg=
−0.17, SE= 0.04, p= 1.0 × 10−5) with muscle strength. Of par-
ticular note, there was no evidence of any genetic correlation
between fall risk with bone mineral density (BMD) or lean mass.
We also used LDSR to explore whether falls are genetically cor-
related with a range of neurological, psychiatric, and behavioral
traits (Supplementary Data 2 and Fig. 3). Falls were strongly
positively correlated with insomnia, neuroticism, depressive
symptoms, and attention deficit hyperactivity disorders, although
the latter two did not pass Bonferroni correction (0.05/49=
0.001). We also observed a small-to-moderate negative correla-
tion with intelligence/IQ (rg=−0.12, SE= 0.04, p= 0.0012) and
subjective well-being (rg=−0.30, SE= 0.05, p= 6.4 × 10−6)
(Supplementary Data 2 and Fig. 3). Medication use is a well-
established risk factor for falls, either directly (affecting balance,
attention, or muscle tone) or indirectly (as proxies of underlying
conditions influencing the risk of falling; joint pain, arthrosis,
cardiovascular diseases among many others). A recent GWAS in
~320,000 individuals from the UK Biobank20 identified 505
independent genetic loci associated with medication use grouped
across 23 categories. Using this data, we observed positive genetic
correlations between fall risk and use of medication such as
opioids, anti-inflammatory and anti-rheumatic drugs, anilids, and
drugs for peptic ulcer and gastro-esophageal reflux disease.
Enrichment of gene expression across tissues. Further, to
quantify the enrichment of the fall-associated SNP signals across
different tissues, we used an extension of LDSR, namely stratified
LDSR (LDSR to specifically expressed genes, LDSC-SEGs), and
identified significant enrichment confined to tissues from the
central nervous system and particularly those derived from the
cerebellum (Supplementary Data 3 and Fig. 4a). We then used
Generalized gene-set analysis of GWAS data (as implemented in
MAGMA21) and also identified significant enrichment of the
signals confined to gene expression in cerebellar tissue (Supple-
mentary Data 4 and Fig. 4b). The latter findings indicate that
biological processes related to movement control of limbs, loco-
motion, adaptation of posture, and dynamic regulation of balance
originated at the cerebellum could play a role shaping the com-
plex mechanisms underlying fall risk.
Mendelian randomization. We then tested whether the asso-
ciation between seven risk factors and falls was causal by using
genetic factors as instruments within a two-sample Mendelian
randomization (MR) approach. Although there are many deter-
minants and conditions that influence the risk of falling, well-
powered GWASs allowing the use of adequate genetic instru-
ments were available for alcohol consumption22, alcohol depen-
dence23, BMI24, and relative hand grip strength defined as the
average of measurements of the right and left hand divided by
weight25. In addition, we evaluated the effect of antihypertensive
medication use on fall risk using genetic variants mapping to
target genes for several antihypertensive drugs. For this purpose,
we used genetic instruments for antihypertensive drug use that
were recently created by Gill et al.26. These antihypertensive drugT
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medications showed no significant evidence for a causal effect.
Alcohol dependence was nominally associated with increased fall
risk (OR= 1.04, 95% confidence interval (95% CI)= 1.01 to 1.08,
P= 0.03) but not after Bonferroni correction. Alcohol con-
sumption also showed no significant evidence for a causal effect
on falls. We did find evidence for a causal effect of BMI (OR=
1.13, 95% CI= 1.06 to 1.20, P < 0.0001) and relative hand grip
strength (OR= 0.41, 95% CI= 0.23 to 0.41, P < 0.0001) on fall
risk (Supplementary Table 2), suggesting that interventions tar-
geted at improving muscle function and weight control may be
successful at decreasing falling risk. The MR-Egger estimate for
hand grip differ from the inverse-variance weighted (IVW) and
WM method. Nevertheless, the I2 of the model was 7.8%, indi-
cating that the MR estimates may suffer from weak instrument
bias and need to be interpreted with caution27.
Discussion
To our knowledge, this is the first GWAS for fall risk performed
to date. Our findings indicate that fall risk is an extremely
heterogeneous polygenic trait with large environmental influ-
ence. Despite such complex genetic architecture, we were able
to identify variants in three loci mapping to chromosomes
5q21.2, 7p21.3, and 19q12. PRSs explained small proportion of
the falls variance in two independent population-based settings.
On aggregate, associated markers show significant enrichment
for genes expressed in cerebellar tissue providing insight
into potential mechanisms mediating fall risk. Shared genetic
variation with fracture risk, muscle strength, medication use,
and other risk factors suggests potential pleiotropic relation-
ships and common biological pathways could mediate diverse
aspects of falling risk.
B-PROOF study fall calendar 
B-PROOF study fall quesonnaire  Roerdam Study fall quesonnaire  
a b c
Fig. 2 Association of falls PRS adjusted for age and sex across several different p-value thresholds (x-axis) within two different populations.
a B-PROOF study falls calendar; b B-PROOF Study falls questionnaire; c Rotterdam Study falls questionnaire. The number on top of the bars represent
p-values of the association between the score and fall risk. Color scale: −log10 of P-value.
Fig. 3 Estimates of the genetic correlation between falls and different traits and medications. The bars around the point estimates represent confidence
intervals. The blue colored point estimates indicate a positive, whereas the red colored point estimates a negative genetic correlation. The lighter shades
are indication of nonsignificant correlation after correcting for multiple testing (p= 0.05/49= 0.001).
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Overall, falls are multifactorial in origin and many different
pathways can contribute to the individual propensity to fall.
Given the polygenic nature of fall risk, it is expected that a large
number of genes influence the risk of falling, each with a very
small contribution. Therefore, large-scale analysis such as the
present UK Biobank study, are required to discover such real,
but weak genetic associations. In addition, the low heritability of
fall risk in our study indicates that there is a strong environ-
mental component underlying the risk of falling. On the other
hand, in twin studies, 35% of the variability in the likelihood of
at least one incident fall and 45% of the variability in the risk for
recurrent falls was attributed to genetic factors13. Notably, it has
been shown that heritability may not be constant during the
lifespan28, with heritability typically decreasing with increasing
age as a consequence of accumulation of environmental influ-
ences with aging29.
We demonstrated that risk for falling has a strong positive
genetic correlation with fracture and low grip strength, whereas
no significant correlation was observed with BMD or lean mass.
This finding implicates a mechanistic pathway influencing frac-
ture risk that is independent of BMD. Fracture occurs when the
force applied to a bone is greater than the overall bone strength.
Low BMD is a key component of bone fragility, i.e., a necessary
but not sufficient cause of fractures30. Although falls may be an
independent predictor of fractures, the fall-related fracture risk
dramatically increases in the presence of low BMD. However, low
BMD alone explains less than one-half of all non-vertebral
fractures31,32 and fractures occurring at higher BMD thresholds
require the presence of other risk factors. Recent studies have
postulated that falls and not osteoporosis per se constitute the
strongest risk factor for fractures in extremely old individuals33,34.
Therefore, falling may be a major contributing factor to the
overall fracture occurrence independent of, and in addition to,
age and BMD35. The strong genetic correlation of falls with
fractures but not BMD corroborates the findings of epidemiolo-
gical studies, while it also provides novel insights into the com-
plex interplay between these traits.
The GWAS signal on chromosome 19q12 (rs2111530; MAF=
0.39) maps in the vicinity (50.6 kb) of TSHZ3, gene encoding a
zinc-finger transcription factor involved in diverse developmental
processes. Recently, a GWAS meta-analysis found a variant
(rs6510186) near this gene associated with total body BMD (TB-
BMD) exclusively in middle-aged adults (45–60 years old)36.
Nevertheless, this variant is unlikely to arise from the same
association signal, as it is not in LD with the top variant from our
GWAS (distance 236.4 kb, r2= 0.003). There is scarce informa-
tion about the function of the TSHZ3 gene, except that it is
suggested to be part of a node of 24 genes with high degree of
connectivity (i.e., hub genes) with strong levels of expression in
early fetal cerebral cortical development37,38. Reduced expression
of TSHZ3 resulting in caspase upregulation has been proposed
to be involved in the pathogenesis of Alzheimer’s disease39.
Fig. 4 GTEx brain tissues were positively enriched for fall-associated variants. a Heritability partitioning enrichment estimates across tissue groups
using LD-SEG. b Tissue enrichment analysis using MAGMA. The most enriched brain tissue is the cerebellum.
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01256-x
6 COMMUNICATIONS BIOLOGY |           (2020) 3:543 | https://doi.org/10.1038/s42003-020-01256-x | www.nature.com/commsbio
Moreover, genetic linkage40,41 and association studies42 have
identified this gene as a potential candidate for autism suscept-
ibility disorders. Altogether, this could suggest a role of TSHZ3 in
cortical development and in the pathogenesis of neurodevelop-
mental disorders. Pending additional evidence of its involvement
in cerebellar biology, our findings suggest its plausible involve-
ment in susceptibility to fall. Annotations relevant to TSHZ3
include both eQTLs and chromatin interactions, which could
further support evidence for the gene involvement in falling
susceptibility. The 7p21.3 variant (rs2709062; MAF= 0.50) is also
intergenic located 127.1 kb upstream of PER4, a non-annotated
pseudogene (PER3s), affiliated with a lncRNA, and of which little
is known about its function. Variants in PER1, PER2, and PER3
(involved in circadian rhythm regulation) have all been identified
as associated with human stature43 and PER1 with estimated
BMD44, among other traits. Further elucidation of regulatory
elements acting through PER4 or other genes will be crucial to
establish its potential relation to falls. Next, the combined meta-
analysis of all participating cohorts yielded another signal
(rs2431108 MAF= 0.33) just surpassing the GWS threshold (P=
4 × 10−8). Therefore, the likelihood of a false positive cannot be
excluded until additional evidence of replication becomes avail-
able, implicating robustly this locus with fall susceptibility. The
SNP maps to 5q21.2 in RP11-6N13.1, a long intervening/inter-
genic noncoding RNA, which does not overlap protein-coding
genes. This SNP have been previously reported in association
with several psychiatric traits such as insomnia, anxiety, neurot-
ism, and depression. Overall, none of the lead SNPs show any
evidence for significant eQTLs and, given the lack of information,
we cannot claim if the closest genes are also the causal genes.
The PRS analyses performed in two independent prospective
cohorts corroborated the polygenic architecture underlying fall
risk. The joint effect of PRS could reliably determine some of the
variation underlying fall risk, implicating variants associated up
to a significance level of 5 × 10−3. The scores constructed from
the two most significantly associated variants were more strongly
associated when using the more sensitive prospective falling
assessment (fall calendars, used in the B-PROOF study), whereas
employing a retrospective definition of falling (as used in the
discovery and in both replication studies) resulted in the strongest
PRSs arising from the inclusion of variants below the genome-
wide significant level. These discrepancies can be the consequence
of many different factors, including differences in assessment
methodology, as retrospective falls were self-reported and may
underestimate the occurrence of falls as a result of recall bias45.
On the other hand, fall calendars are considered the best tool
available for reliable fall assessment in older adults, providing
more accurate information on falls (i.e., prospective assessment)
as participants report fall incidents each week. Nevertheless, the
PRS results should be interpreted with caution given the low SNP
heritability of fall risk46.
Medication use is recognized as an important risk factor for
falling, whereas polypharmacy among the elderly has increased
dramatically in the past decades47. Epidemiologically, several
types of psychotropic, cardiac, and analgesic drugs are associated
with falls, typically including sedatives and hypnotics such as
benzodiazepines, antipsychotics, antidepressants, diuretics, anti-
epileptics, and opioids48–50. In line with the epidemiological
relationship, we found that falls had significant genetic correla-
tion with the use of most of these medication categories and in
the expected directions. The strongest genetic correlation was
observed with opioids and anti-inflammatory drug use. These
findings suggest that some of the genetic predisposition for falling
risk is shared with the use of medication associated with falling
risk. Yet, the causal mechanistic pathways can differ across dif-
ferent pleiotropic (vertical vs. horizontal) relationships. Vertical
pleiotropy will be relevant for medications causally related to fall
risk, where the genetic correlation with a condition will also be
related to the drug indication all together, pointing to a common
biological pathway influencing all three components (fall risk,
condition, and medication). Another form of vertical pleiotropy
will be expected to arise when the medication is not necessarily
causally related to fall risk (e.g., NSAIDs), but the condition
driving the drug indication (e.g., arthrosis or other musculoske-
letal disorder affecting mobility) will be the causal factor leading
to falling. True horizontal pleiotropy is much more difficult to
ascertain in a largely polygenic trait51 such as falling risk, but we
can expect it to arise with specific conditions through biological
pathways influencing neurological/cerebellar function as further
discussed below.
Reduced hand grip strength and increased BMI are risk factors
identified by MR to be causally related to fall risk. A decrease in
relative hand grip strength was observed to be causally associated
with an increased risk of falling. Therefore, muscle weakness is a
clinically relevant risk factor for falls that should be assessed and
treated in older adults at risk for falls52. Our MR results also
support the evidence from recent observational studies that older
obese individuals have greater risk of falling53,54. The exact
mechanisms by which BMI increases the risk of falling in older
adults remain unclear and require further exploration. One pos-
sible explanation is that obesity may alter balance control, which
is an important risk factor for falling55.
Further, using grouped cell type and tissue expression analysis,
the cerebellum was the most significant enriched tissue. The
cerebellum plays an important role in motor control and main-
taining postural balance56. Cerebellar disorders can lead to
orthostatic hypotension, vertigo, and syncope, all important risk
factors for falls57,58. All these factors can increase the fall risk,
either individually or combined.
Some limitations of our study need to be noted. Although self-
reported measures can appear robust for other phenotypes such
as birthweight59, it is possible that recall bias may have influenced
the assessment of fall risk. Falling is a complex, heterogeneous
trait and, in most of the cases, it may be attributed to non-genetic
factors (e.g., medication use, mobility disorders, and hazardous
household environments). Also, given the UKBB age range
(40–69 years) and inclusion of European ancestry individuals
only, we cannot assume that our results generalize to other age
groups in whom falls are more common, and/or ancestral
populations. There are other factors explaining the large hetero-
geneity underlying fall risk. Different fall patterns are observed
between young and old people, whereas on the other hand, the
number of co-morbid conditions and medication use associated
with falls also increase with age60. The genetic susceptibility for
falls may be of less importance in individuals with multiple fall
risk factors regardless of age. Different factors can increase the
risk of falling across different age decades. Next, the heritability
and genetic susceptibility of fall risk might be higher in indivi-
duals with recurrent falls, which we were not able to test in the
current study. Similarly, a GWAS on medication use-related falls
is warranted to address the causal role of medication and
understand further the biological pathways underlying fall risk.
Moreover, participants from the UK Biobank were included in
the GWASs of both relative hand grip strength and falls. This
sample overlap might increase the probability of a Type I error
resulting in false-positive findings; thus, it needs to be replicated
in independent efforts. There is an ongoing collection of hospital
admission data in the UK Biobank that may provide an improved
and well-powered resource for future research. Lastly, in our
GWAS study, we only tested SNPs for association with falling
risk. We did not consider other forms of genetic variation such
as structural changes, i.e., copy number variations, in/dels or
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inversions, which may also contribute to the genetic landscape of
falling risk. Similarly, we also did not test for potential epigenetic
modifications.
In conclusion, our study demonstrated that fall risk is a heri-
table, heterogeneous, and polygenic trait genetically correlated
with fracture risk and grip strength, among other neuropsychia-
tric and medication traits. The cerebellum tissue enrichment of
fall-associated variants supports the mediation of postural balance
in the etiology of falls. Our study provides novel biological insight
that can be used for optimizing strategies directed at preventing
falls and their associated deleterious consequences in aging
individuals.
Methods
Study population. Our analyses were performed using data from the UK Biobank
study. Briefly, the UK Biobank is a large prospective cohort study of approximately
a half-million adult (ages 40–69 years) participants living in the United Kingdom,
recruited from 22 centers across the United Kingdom in 2006–201061. We use a
subsample of the total study, who were identified as or white European ancestry
using a combination of genetic principal components and self-reported ethnicity.
Ethical approval was granted by the Northwest Multi-centre Research Ethics
Committee and written informed consent was obtained from all participants.
Assessment of falls. The number of falls in the UK Biobank was self-reported
via a touch screen questionnaire. In total, 89,076 individuals have reported that
they have had one or more falls answering to the question “In the last year have
you had any falls?” Individuals who selected “prefer not to answer” or “do not
know” were set to missing; the rest of the population were classified as controls
(N= 362,103).
GWAS data and imputation. The majority of UK Biobank participants were
genotyped with the Affymetrix UK Biobank Axiom Array (Santa Clara, CA, USA),
whereas 10% of participants were genotyped with the Affymetrix UK BiLEVE
Axiom Array. Imputation was performed using the Haplotype Reference Con-
sortium (HRC) panel62 and was carried out with the IMPUTE2 software. Detailed
quality control and imputation procedures are described elsewhere63. Only parti-
cipants of white European ancestry (identified using a k-means clustering approach
based on genetic principal components, as well as self-identification) were
analyzed.
Association analysis. Genetic association analyses were performed using BOLT-
LMM64. Briefly, this method uses a linear mixed model to account for relatedness
and population structure using a relationship matrix. Fall risk was corrected for age
and sex in logistic regression models. SNP association was tested for all autosomal
variants. Individuals were excluded based on unusually high heterozygosity or >5%
missing genotype rate, a mismatch between self-reported and genetically inferred
sex. SNP exclusions were made based on low MAF (<1%) and low imputation
quality (info < 0.3). SNPs with P ≤ 5 × 10−7 were considered suggestive, whereas
SNPs with P ≤ 5 × 10−8 were considered GWS.
Replication and meta-analysis. Suggestive SNPs were selected based on an
arbitrary P-value threshold of ≤5 × 10−7 and were later followed for replication in
smaller and older prospective population-based studies, i.e., the Rotterdam Study
(1009 cases and 4925 controls) and B-PROOF (1206 cases and 1364 controls)
cohorts. The Rotterdam Study is an ongoing population-based cohort within a
suburb in Rotterdam. Its design, objective, and methods have been described in
detail16. Briefly, the study was initiated in 1989 and 7983 participants aged 55 years
and above were included. Participants were interviewed and underwent an
extensive set of examination that were repeated every 4–5 years. B-PROOF has
been also described in detail elsewhere15. In short, it is a multi-center, randomized,
placebo-controlled, double-blinded trial investigating the efficacy of vitamin B and
folic acid supplementation on the prevention of fractures in people aged 65 years
and older. In total, 2919 participants were included and followed for 2–3 years.
Both studies have been approved by the medical ethics committee. In the Rot-
terdam Study, fall history was assessed from baseline questionnaire. In B-PROOF,
retrospective and prospective falls were reported. Prevalent falls were assessed
using a baseline questionnaire, whereas fall incidences during follow-up were
reported prospectively using a falls’ calendar in a period of 2–3 years. The baseline
questionnaire in both cohorts consisted of a single question: “Have you fallen in the
past 12 months?” In B-PROOF, we used fall incidence for the GWAS analysis, as it
provided larger sample size (500 participants had missing information on prevalent
falls). Both studies used commercially available genome-wide arrays to genotype
their participants. SNPs were imputed to the HRC reference panel62 (build 37)
using the Michigan Imputation Server.
Gene-based testing and functional mapping. Gene-based GWAS analysis was
carried out with MAGMA 1.621 using the default settings implemented in
FUMA65. The analysis was performed using the falls GWAS summary statistics as
input file where each SNPs were assigned to a gene using the NCBI 37.3 gene
definition. First, each individual SNP in a gene was tested separately and SNP p-
values within a gene were aggregated to derive a gene test statistic21. According to
the number of tested genes, the level of gene-wide significance was set at 0.05/
18,615= 2.7 × 10−6. The gene-base p-values were then utilized to perform gene-set
enrichment analyses using MAGMA (implemented in FUMA); where gene
expression values for 53 specific tissue types were obtained from GTEx66. The
gene-set enrichment analysis estimated the association between highly expressed
genes in a specific tissue and genetic associations from the gene-based analysis.
Functional annotation (i.e., prioritization, annotation, and interpretation) of
GWAS results was also performed using FUMA65.
Polygenic risk scores. We used imputed genotype data from the B-PROOF and
the Rotterdam Study cohorts to calculate PRSs for each participant using the
PRsice software18. For the construction of the PRS, we first selected SNPs with P <
0.05, MAF > 0.05, and imputation quality > 0.3 from the UK Biobank GWAS. Next,
we excluded SNPs with MAF < 0.05 and imputation quality < 0.3 in the Rotterdam
study and B-PROOF. In total, 436,130 SNPs passed these thresholds and were
followed in the PRS analysis. Seventeen PRS sets were created for a series of P-value
thresholds ranging from 5 × 10−8 to 1. SNPs were pruned with PLINK (version 1.9)
using stringent clumping thresholds based on both linkage disequilibrium and
distance using an r2 of 0.05 and a distance of 300 kb. We tested each of the 17 PRSs
in relation to fall risk adjusted for age and sex stratified by cohort using logistic
regression models. In the B-PROOF study, we tested the scores with both prevalent
and incident falls. We reported the proportion of variance explained (based on R2)
by each fall PRS.
Linkage disequilibrium score regression. SNP-based heritability and genomic
inflation. To estimate the genomic inflation in the data and the SNP-based
heritability of falls, we used LDSR67. The LDSR intercept provides estimate
of inflation due to population stratification or model misspecification; impor-
tantly, it is not unduly affected by polygenicity68. On the other hand, the LDSR
slope provides estimate of the heritability explained by all SNPs67. The analyses
were restricted to HapMap3 SNPs with MAF > 5% in the 1000 Genomes Eur-
opean reference population. Finally, we used pre-calculated LD scores from the
same reference population. (https://data.broadinstitute.org/alkesgroup/
LDSCORE/).
Shared genetic architecture of falls and other traits. To estimate the genetic corre-
lation between falls and other complex traits and diseases, we used (cross-trait)
LDSR19 as implemented in the online web utility LDHub69. This method uses the
cross-products of summary test statistics from two GWASs and regresses them
against a measure of how much variation each SNP tags (its LD score)70. The data
base of the LDHub web utility contains a range of data relating to genetic effects on
common diseases and phenotypes. From the variety of traits available on LD-hub,
we selected 17 cognitive, personality, psychiatric, and neurological traits/disorders a
priori that can affect the function of the motor and sensory systems. These traits
are essential for the planning and execution of the everyday movements and for the
control of posture and balance. Further, we selected seven additional muscu-
loskeletal traits (including fractures; site-specific BMD of the femoral neck and
lumbar spine and TB; appendicular and total lean mass; and hand grip muscle
strength to better understand the relationship between falling risk and the risk of
fracture). In addition, locally, we estimated the genetic correlation between fall risk
and 22 medication classes from the latest GWAS on medication use20, where
medications were self-reported and classified using the Anatomical Therapeutic
Chemical Classification System into 1752 categories (with minimum 10 users) after
careful evaluation of the medication record data. We accounted for multiple testing
by using a conservative Bonferroni correction for 46 tests (0.05/46= 0.001).
Finally, we also included in the LDSR analyses BMI, alcohol consumption, and
alcohol dependence tested for causal effects on falling risk using the MR approach.
Stratified heritability and functional enrichment and tissue specificity analyses of
fall-associated variants. To identify tissues and cell types that are likely to be
involved in falling susceptibility, we applied LDSC-SEG71. Annotation data were
obtained from the LD score website (https://github.com/bulik/ldsc). For each tis-
sue, we ranked genes by a t-statistic for differential expression, using sex and age as
covariates, and excluding all samples in related tissues71. For example, we com-
pared expression in cerebellum samples to expression in all non-brain samples. We
used the top 10% of genes by this ranking and used stratified LDSR to estimate the
contribution of genomic annotations to per-SNP falls heritability, adjusting for 24
main annotations categories (e.g., coding, untranslated region (UTR), promotor,
and intron) in the baseline model72. In addition, we performed MAGMA Tissue
Expression analysis (using FUMA) to test relationships between tissue-specific gene
expression and disease–gene associations. MAGMA was performed using the result
of gene-set analysis (gene-based P-value) and tested for one side (greater) with
conditioning on average expression across all tissue types.
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Mendelian randomization. We used the largest previously published GWAS
meta-analyses of the traits included in the MR analyses. The construction of genetic
instruments for antihypertensive drug targets are explained in details by Gill
et al.26. To reduce potential bias due to population stratification, we restricted the
analyses to studies with participants of European descent. In addition, instrumental
variables which were nominally (p < 0.05) associated with fall risk were excluded
from the analysis. The resulting individual SNP effect estimates were pooled using
IVW meta-analysis. We applied a conservative Bonferroni corrected threshold to
account for the multiple testing (i.e., α= 0.007, because seven exposures were
assessed). To test the third assumption (a lack of pleiotropic effects of the SNPs on
the outcome, independent of the exposure), we used MR-Egger regression.
Moreover, as sensitivity analyses for robust causal inference, we additionally per-
formed MR analyses using a weighted median estimator. The analyses were con-
ducted with the R-package MendelianRandomization73.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data analyzed in the current study were provided by the UK Biobank Study (www.
ukbiobank.ac.uk) under UK Biobank application number 24268. The datasets generated
during the current study are available at the GEFOS website http://www.gefos.org/. The
data source for Fig. 1 was the falls GWAS summary statistics, which are available at the
GEFOS website http://www.gefos.org/. Additional datasets that have been used for analysis
can be found on the links to their corresponding reference papers and URLs (see below).
Code availability
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LDSC (LD SCore) https://github.com/bulik/ldsc
LD Hub http://ldsc.broadinstitute.org/ldhub
GTEx Portal https://www.gtexportal.org/home/
PRSice-2: Polygenic Risk Score software https://www.prsice.info/
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